Innovative vaccines for a healthier world

Isconova AB is a leading international vaccine adjuvant company. With its vast knowledge of vaccine systems Isconova develops vaccines together with partners in the human and veterinary markets.

The first vaccine using Isconovas nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2005. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix-M™. Isconova’s partners include Crucell, Pfizer, Merck & Co., The Jenner Institute and Genocea. The Company is headquartered in Uppsala, Sweden. Isconova was listed on NASDAQ OMX First North (ticker: ISCO) in November 2010. Pareto Öhman AB is the Company’s Certified Adviser.

Launched vaccines with Isconova's adjuvant

Canvac CCi® - Bordetella bronchiseptica (2007, Pfizer)

Equilis® Prequenza - Equine influenza (2006, Intervet, now MSD animal health)

Pestigard® - Bovine BVDV (2003, Pfizer)

Equity® - Equine LHRH (2002, Pfizer)

Equip® - Equine influenza (1993, Schering-Plough. From Oct. 2008, Pfizer)